EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudieOpen Access · CC BY 4.0

Evaluation of the Novel RITA MTBC Assay for Tuberculosis Detection: A Pilot Comparison with GeneXpert and BD MAX™

Tomasz Bogiel iD, Małgorzata Zimna, Renata Żebracka, Katarzyna Dziwnik, Monika Montowska, Dorota Krawiecka, Dawid Nidzworski iD, Marta Skwarecka iD, Kasjan Szemiako, Sabina Nidzworska iD, Marcin Woźniak iD, Kamil Drożdż und 1 weitere

Pathogens · 2025

DOI: 10.3390/pathogens15010021 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pathogens, 2025. Verfasst von Tomasz Bogiel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Propaedeutics of Medicine and Infection Prevention Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in To…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Nucleic Acid Amplification Techniques, Molecular Diagnostic Techniques, Tuberculosis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nicolaus Copernicus University funds for the basic research activity of the Microbiology Department Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis is still one of the leading infectious causes of morbidity and mortality worldwide. Rapid diagnosis is essential for effective treatment and control of tuberculosis transmission. In recent years, nucleic acid amplification tests (NAATs), such as GeneXpert MTB/RIF, BD MAX™, Xpert MTB/RIF-Ultra, have significantly improved tuberculosis diagnostics. However, they mainly require expensive and advanced equipment. The aim of our study was to assess the usefulness of the novel RITA MTBC assay in this diagnostic context. A total of 61 clinical specimens were tested using the RITA MTBC assay in comparison with established molecular diagnostic platforms (GeneXpert and BD MAX™), used as molecular reference assays. Culture and microscopy were performed as part of initial clinical assessment, but the comparative analysis focused on molecular assays to provide a relevant evaluation of diagnostic performance. Among 31 samples previously identified as positive for M. tuberculosis DNA, the assay correctly detected 30 (LOT HPA01/20230601) and 29 (LOT HPA01/20230602). Of 30 negative samples, 28 and 30 were confirmed negative for the respective lots. These results correspond to an average sensitivity of 95% and an average specificity of 97%. The kit demonstrated diagnostic performance that meets requirements for molecular testing in tuberculosis, with sensitivity and specificity comparable to established platforms, although further validation on larger sample sets is necessary. Nevertheless, its excellent specificity, rapid turnaround time, and operational simplicity, make it especially well-suited for decentralized or resource-limited settings. These findings underscore the potential of RITA MTBC as a valuable diagnostic tool in both routine clinical settings and in populations with limited access to healthcare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisNucleic Acid Amplification TechniquesMolecular Diagnostic TechniquesTuberculosisHumansSensitivity and SpecificityPilot ProjectsRapid Diagnostic TestsDNA, Bacterial

Stichwörter der Autor:innen

BD MAX™ MDR-TBGeneXpert MTB/RIFMycobacterium tuberculosismolecular diagnosticsnucleic acid amplification testsrapid diagnosticstuberculosis

Substanzen

DNA, Bacterial

Autor:innen und Institutionen

  • Department of Propaedeutics of Medicine and Infection Prevention Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 9 Maria Skłodowska-Curie Street, 85-094 Bydgoszcz, Poland.
  • Clinical Microbiology Laboratory, Dr. Antoni Jurasz University Hospital No. 1 in Bydgoszcz, 9 Maria Skłodowska-Curie Street, 85-094 Bydgoszcz, Poland.
  • Department of Microbiological Diagnostics, Kujawsko-Pomorskie Pulmonology Centre in Bydgoszcz, 85-326 Bydgoszcz, Poland.
  • Institute of Biotechnology and Molecular Medicine, 25 Kampinoska Street, 80-180 Gdansk, Poland.
  • Department of Forensic Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland.
  • Department of Molecular Medical Microbiology, Jagiellonian University Medical College in Cracow, 31-121 Krakow, Poland.

ORCID-Profile: Tomasz Bogiel, Dawid Nidzworski, Marta Skwarecka, Sabina Nidzworska, Marcin Woźniak, Agnieszka Krawczyk

Förderung

  • Nicolaus Copernicus University funds for the basic research activity of the Microbiology Department Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland

Zitieren

APA

Bogiel, T., Zimna, M., Żebracka, R., Dziwnik, K., Montowska, M., Krawiecka, D., Nidzworski, D., Skwarecka, M., Szemiako, K., Nidzworska, S., Woźniak, M., Drożdż, K., & Krawczyk, A. (2025). Evaluation of the Novel RITA MTBC Assay for Tuberculosis Detection: A Pilot Comparison with GeneXpert and BD MAX™. Pathogens. https://doi.org/10.3390/pathogens15010021

Vancouver

Bogiel T, Zimna M, Żebracka R, Dziwnik K, Montowska M, Krawiecka D, et al. Evaluation of the Novel RITA MTBC Assay for Tuberculosis Detection: A Pilot Comparison with GeneXpert and BD MAX™. Pathogens. 2025. doi:10.3390/pathogens15010021

BibTeX
@article{Bogiel2025,
  author = {Bogiel, Tomasz and Zimna, Małgorzata and Żebracka, Renata and Dziwnik, Katarzyna and Montowska, Monika and Krawiecka, Dorota and Nidzworski, Dawid and Skwarecka, Marta and Szemiako, Kasjan and Nidzworska, Sabina and Woźniak, Marcin and Drożdż, Kamil and Krawczyk, Agnieszka},
  title = {Evaluation of the Novel RITA MTBC Assay for Tuberculosis Detection: A Pilot Comparison with GeneXpert and BD MAX™},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens15010021}
}
Kostenlos starten →